Phase 2 Open Label Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)

Part of paid clinical trials in Burlington, Massachusetts.

Sponsor
Maryanne Makredes Senna
Study ID
NCT07671157
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Frontal Fibrosing Alopecia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Delgocitinib — DRUG
    Everyone in this study receives the study drug (delgocitinib)

Study Details

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational study drug to learn whether the delgocitinib 20 mg/g cream works in treating a specific disease. "Investigational" means that the delgocitinib 20 mg/g cream is being studied.

Key Dates

Start date
Sep 10, 2026
Status verified
Jun 2026
Primary completion
Oct 10, 2027
Completion
Oct 10, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: study drug

Primary Outcome Measure

Hairline measurements [ Time Frame: from 0 to 24 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Lahey ClinicBurlingtonMassachusetts01805
Hunt
[email protected]
7819991853

Find similar trials in Burlington, MA

By research site
Lahey Clinic· Burlington, MA

Related Studies